Dihydroergotamine

SAN DIEGO — Treating migraine with a novel formulation of dihydroergotamine powder was linked to favorable outcomes including significant headache pain reduction at 48 hours post dose that was extended to 12 months.

AUSTIN, Texas — Sustained freedom from pain and the most bothersome migraine symptom was achieved in more patients treated with investigational STS 101 compared with placebo, according to a study presented here.

An integrated ambulatory care model that had infusion capacity for pediatric refractory headache appeared feasible and beneficial for these patients, according to a quality improvement study.

Updated analyses from the phase 3, open-label STOP 301 study of nasal dihydroergotamine-based INP104 for the treatment of migraine provides new safety and tolerability data regarding nausea as well as nasal and cardiovascular outcomes.

Biotech company Impel Neuropharma announced that its precision olfactory delivery device, or POD, safely delivered the company’s nasal dihydroergotamine-based INP104 treatment to patients with migraine.